Wallaby Medical has acquired German company phenox, including femtos, in a deal valued at nearly $543m (€500m), including milestone payments. 

Established in 2005, phenox offers a portfolio of neurovascular devices for the treatment of both ischemic and haemorrhagic strokes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The key product line of the company comprises the p64/p48 range of flow diverters, to treat intracranial aneurysms, and the pRESET range of stent retrievers for the mechanical thrombectomy of ischemic strokes. 

Furthermore, phenox provides coating technologies to improve permanent and short-term implants. 

Wallaby also acquired femtos, which acts as an incubator for advanced medical technologies, focusing on the development and manufacturing of next-generation neurovascular devices to treat stroke. It has capabilities in femto-second laser technology, allowing it to produce stents and other implantable devices, and currently has two CE approved products.

The takeover will allow the merged company to become a leader in offering an extensive range of neurovascular technologies and solutions to customers and patients globally, including in the US, Europe, Japan, China and various other markets.

Wallaby CEO Michael Alper will serve as the CEO of the merged company while phenox founder professor Dr-Ing Hermann Monstadt will act as phenox’s managing director. 

Furthermore, all existing product brands of phenox will be retained.

Wallaby used the proceeds from its Series D round to fund the deal.

Alper said: “By combining the highly complementary product pipelines of the two companies, we will be able to offer a full spectrum of world-class interventional neurovascular products and solutions. 

“The broadened product portfolio, enhanced R&D capability and expanded geographic coverage will provide Wallaby-phenox with an unparalleled competitive edge as we strive to become a global leader in the neurovascular market.”